Please provide your email address to receive an email when new articles are posted on . When a patient has a cataract and glaucoma, my mindset is not “this is a cataract patient who happens to have ...
Please provide your email address to receive an email when new articles are posted on . This combined procedure provides the benefit of improving vision and decreasing IOP postoperatively, which can ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...
Multiple 5-, 6-, 7- and 8-Year Real-World Studies Published, Demonstrating Leading Efficacy & Safety Across the Entire Glaucoma Disease Spectrum SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos ...
Glaukos Corp. (NYSE: GKOS) is seeing its continued efforts to bring new and improved products to the micro-invasive glaucoma surgery (MIGS) market pay off. MIGS-related net sales for the San Clemente ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...
(RTTNews) - Glaukos Corp. (GKOS) has submitted a supplemental pre-market approval application to the FDA for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results